SARS-CoV-2 - Camostat mesylate - Therapeutic Candidates

SARS-CoV-2 - Camostat mesylate - Therapeutic Candidates


Camostat is a serine protease inhaler used, in the form of camostat mesilate, for the treatment of various pathologies such as certain cancers or fibrosis in kidney diseases.
CoV-2-CoRNA exploits the cell entry receptor protein, angiotensin II converting enzyme (ACE-2), to access and infect human cells. The interaction between ACE-2 and the lead protein is not in the active site. This process requires the serine protease TMPRSS2. Camostat mesilate is a potent inhibitor of serine protease. Through research on the SARS-CoV-2 coronavirus and its closely related cell entry mechanism, it has been shown that the cellular entry of SARS-CoV-2 can be blocked by camostat mesilate. In mice, camostat mesilate administered at concentrations similar to the clinically achievable concentration in humans reduced mortality from SARS-CoV-2 infection from 100% to 30-35%. In addition, another study showed that camostat mesilate reduced SARS-CoV-2 infection of Calu-3 cells.

Search result : 62 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 31
  • Inhibitor/Antagonist/Agonist 36
  • Biochemicals 24
  • Protein/peptide 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
B2082-10mg
 10mg 
orb1224533-5mg
 5mg 
orb1224533-100mg
 100mg 
orb638792-10mg
 10mg 
orb638792-50mg
 50mg 
orb1224533-10mg
 10mg 
orb1224533-200mg
 200mg 
orb1224533-50mg
 50mg 
orb1224533-25mg
 25mg 
orb1742905-50mg
 50mg 
orb1742905-10mg
 10mg 
332-10779-1
 5mg 
332-10779-6
 200mg 
M2487-10mg
 10mg 
332-10779-2
 10mg 
332-10779-3
 25mg 
332-10779-4
 50mg 
332-10779-5
 100mg 
abx076865-50mg
 50mg 
M2487-50mg
 50mg